| Ms Vera Sichko-seltzer, MS, CNM | |
|
330 Mount Auburn St, Cambridge, MA 02138-5502 | |
| (617) 499-5130 | |
| (617) 499-5103 |
| Full Name | Ms Vera Sichko-seltzer |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 330 Mount Auburn St, Cambridge, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265441141 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | RN 2276585 (Massachusetts) | Primary |
| Entity Name | Massachusetts Institute Of Technology |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346308723 PECOS PAC ID: 5597658666 Enrollment ID: O20040203000789 |
News Archive
For newborn infants at risk of infection with group B streptococcal (GBS) bacteria, screening blood tests cause extra pain and anxiety—without increasing detection of early-onset GBS disease, reports a study in the October issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Human glioblastoma multiforme, one of the most common, aggressive and deadly forms of brain cancer, is notoriously difficult to study. Scientists have traditionally studied cancer cells in petri dishes, which have none of the properties of the brain tissues in which these cancers grow, or in expensive animal models.
IsoRay, Inc. announced today that it has completed a license agreement with Dr. Reddy's Laboratories for exclusive worldwide licensing rights to Iotrex, a liquid iodine radiation, for use in brain cancer treatment.
As reported in a March 18, New York Times editorial, "Honest Food Labels," FDA Commissioner, Margaret Hamburg, M.D., publicized letters to 17 food companies accusing them of - "masking undesirable ingredients" - in their products. She also emphasized the importance of "providing nutrition information that consumers can rely on."
Tetraphase Pharmaceuticals, Inc., yesterday presented new clinical and preclinical data for its lead drug candidate, TP-434, which demonstrated the novel antibiotic as a once daily intravenous (I.V.) monotherapy capable of treating multidrug-resistant gram-negative pathogens while also having potency and broad spectrum coverage of other serious and multidrug resistant gram-positive pathogens.
› Verified 6 days ago
| Entity Name | Mt Auburn Professional Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992750996 PECOS PAC ID: 6103725031 Enrollment ID: O20040527001374 |
News Archive
For newborn infants at risk of infection with group B streptococcal (GBS) bacteria, screening blood tests cause extra pain and anxiety—without increasing detection of early-onset GBS disease, reports a study in the October issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Human glioblastoma multiforme, one of the most common, aggressive and deadly forms of brain cancer, is notoriously difficult to study. Scientists have traditionally studied cancer cells in petri dishes, which have none of the properties of the brain tissues in which these cancers grow, or in expensive animal models.
IsoRay, Inc. announced today that it has completed a license agreement with Dr. Reddy's Laboratories for exclusive worldwide licensing rights to Iotrex, a liquid iodine radiation, for use in brain cancer treatment.
As reported in a March 18, New York Times editorial, "Honest Food Labels," FDA Commissioner, Margaret Hamburg, M.D., publicized letters to 17 food companies accusing them of - "masking undesirable ingredients" - in their products. She also emphasized the importance of "providing nutrition information that consumers can rely on."
Tetraphase Pharmaceuticals, Inc., yesterday presented new clinical and preclinical data for its lead drug candidate, TP-434, which demonstrated the novel antibiotic as a once daily intravenous (I.V.) monotherapy capable of treating multidrug-resistant gram-negative pathogens while also having potency and broad spectrum coverage of other serious and multidrug resistant gram-positive pathogens.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Vera Sichko-seltzer, MS, CNM 330 Mount Auburn Street, Cambridge, MA 02138-5502 Ph: (617) 499-5130 | Ms Vera Sichko-seltzer, MS, CNM 330 Mount Auburn St, Cambridge, MA 02138-5502 Ph: (617) 499-5130 |
News Archive
For newborn infants at risk of infection with group B streptococcal (GBS) bacteria, screening blood tests cause extra pain and anxiety—without increasing detection of early-onset GBS disease, reports a study in the October issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Human glioblastoma multiforme, one of the most common, aggressive and deadly forms of brain cancer, is notoriously difficult to study. Scientists have traditionally studied cancer cells in petri dishes, which have none of the properties of the brain tissues in which these cancers grow, or in expensive animal models.
IsoRay, Inc. announced today that it has completed a license agreement with Dr. Reddy's Laboratories for exclusive worldwide licensing rights to Iotrex, a liquid iodine radiation, for use in brain cancer treatment.
As reported in a March 18, New York Times editorial, "Honest Food Labels," FDA Commissioner, Margaret Hamburg, M.D., publicized letters to 17 food companies accusing them of - "masking undesirable ingredients" - in their products. She also emphasized the importance of "providing nutrition information that consumers can rely on."
Tetraphase Pharmaceuticals, Inc., yesterday presented new clinical and preclinical data for its lead drug candidate, TP-434, which demonstrated the novel antibiotic as a once daily intravenous (I.V.) monotherapy capable of treating multidrug-resistant gram-negative pathogens while also having potency and broad spectrum coverage of other serious and multidrug resistant gram-positive pathogens.
› Verified 6 days ago
Gisela Jung-seifert, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 1493 Cambridge St, Cambridge, MA 02139 Phone: 617-665-2229 | |
Kam-ling L Ma, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 1493 Cambridge St, Cambridge, MA 02139 Phone: 617-665-1309 | |
Ms. Juhi J Khamar, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 1493 Cambridge St, Cambridge, MA 02139 Phone: 617-665-1616 Fax: 617-665-1976 | |
Kathellen T Reist, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 1493 Cambridge St, Cambridge, MA 02139 Phone: 617-665-2229 | |
Mrs. Cassandra Kugler, CNM, WHNP-BC Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 1493 Cambridge St, Cambridge, MA 02139 Phone: 314-960-4449 | |
Margi L Coggins, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 1493 Cambridge St, Cambridge, MA 02139 Phone: 617-665-2229 |